GPT and metabolic dysfunction-associated steatotic liver disease: Finally, a study of NAFLD patients with type 2 diabetes who did not respond to incretin-based therapy showed that SGLT-2 inhibitor treatment resulted in good glycemic control, reduced body weight, normalized ALT levels, and a reduced Fibrosis-4 index (78).